Roche Obesity Shot Reduced Body Weight By 15.5% In Trial

(MENAFN- Swissinfo) Roche's experimental obesity shot enicepatide cut both blood sugar and body weight in type-2 diabetes patients who were overweight or obese in a mid-stage trial. Select your language

Generated with artificial intelligence. Listening: Roche obesity shot reduced body weight by 15.5% in trial This content was published on September 23, 2026 - 10:02 4 minutes Bloomberg

Patients receiving the highest 24-milligram dose had a 2.65% reduction in HbA1c – a measure of blood sugar – and lost an average 15.5% of their body weight after 48 weeks with no plateau observed, Roche said.

The data“look competitive” against results for rival drugs in Phase 3 trials, Goldman Sachs analyst James Quigley and colleagues said. They cautioned, however, that they need to see detailed placebo-adjusted data and the results replicated in Phase 3 trials to confirm the benefit.

Roche shares fell 0.19% at the end of the trading day in Zurich.

The Swiss drugmaker is seeking to compete with Eli Lilly & Co and Novo Nordisk A/S with a once-weekly shot that works similarly to Lilly's Zepbound - by simultaneously activating the GLP-1 and GIP hormones involved in regulating metabolism. The global market for weight-loss drugs is estimated to reach as much as $150 billion.

More More New treatments Can Swiss pharma giant Roche reshape the obesity market?

This content was published on Apr 2, 2026 Swiss pharmaceutical firm Roche is investing billions in new obesity treatments in hopes of breaking into a highly competitive market.

Read more: Can Swiss pharma giant Roche reshape the obesity ma

MENAFN23092026000210011054ID1111705808